Kristina Burow

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin.

Part of ARCH Venture Partners LLC, ARCH Venture Partners LP operates as a venture capital firm. The company is based in Dover, DE. The company was founded by Robert Taylor Nelsen.

Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI.

Sapphire Energy, Inc. develops and produces algae-based crude oil products. It uses sunlight, CO2, non-potable water, non-arable land and nutrients in outdoor ponds to produce biomass that can then be converted into high-value oils, aquaculture and animal feeds and fuels products. The company was founded by Mike Mendez, Kristina Marie Burow, Nathaniel Eames David and Jason L. Pyle in May 2007 and is headquartered in San Diego, CA.

Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA.

Kilimanjaro Energy, Inc. develops advanced technologies to capture atmospheric carbon-dioxides. The company was founded by William W. Gridley, Klaus S. Lackner, Allen B. Wright and Nathaniel Eames David in 2004 and is headquartered in New York, NY.

Epirium Bio, Inc. develops therapeutics for orphan and rare diseases characterized by impairment of the skeletal muscle, cardiac and neuronal systems. The company was founded in 2008 by Alan Stewart Maisel, Sundeep Dugar, and Francisco Villarreal and is headquartered in Los Altos Hills, CA.

LearnZillion, Inc. engages in the development of a web-based education tool and video library of math and literacy lessons. LearnZillion was founded by Eric Westendorf and Alix Guerrier in 2011 and is headquartered in Washington, DC.

Trelys, Inc. owns and operates biotechnology products. The company was founded by Jay Kouba and is headquartered in Hayward, CA.

Novartis Bioventure Fund focuses on companies operating in the field of life science technology. The geographical focus includes the US, Canada, UK and Switzerland. The fund invests in biotechnology, pharmaceuticals and medical device products. It invests in all stages of financing and also invests in mezzanine transactions.

National Venture Capital Association provides business association services. It facilitates networking opportunities and provides research data to its members. The company is headquartered in Washington, DC.

Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities.

Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA.

Novartis Venture Fund provides early stage venture capital to companies in Europe, North America and Asia. The fund's focus is on the development of novel therapeutics and platforms, therefore it focuses on such sectors as Biotechnology and Biopharma. The fund makes seed and early stage investments ranging up to USD 30 million per company over its life. The fund makes follow-on and co-investments.

AgBiome LLC provides early stage research and discovery to the agriculture industry. It develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. The firm applies genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and yield. The company was founded by Jeff Dangl, John N. Couch, Paul Schulze-Lefert, Scott J. Uknes, John Ryals, Eric R. Ward, and Mike Koziel in 2012 and is headquartered in Research Triangle Park, NC.

Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA.

Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA.

Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA.

AgTech Accelerator Corp. focuses on discovering and developing agricultural technology companies. It offers finance to agricultural firms. The company was founded in 2003 and is headquartered in Durham, NC.

Reactive Biosciences Inc. engages in the design and developemnt of novel solutions targeting needs in crop protection, animal health and human health. It specializes in chemistry, research, and biotechnology. The company was founded by Stephen J. Benkovic, Gerald R. Fink, Lucy Shapiro, Paul R. Schimmel and C. Tony Liu in 2015 and is headquartered in Durham, NC.

Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA.

Autobahn Therapeutics, Inc. is a thyromimetics drug discovery company. It serves patients with neurodegenerative disorders. The company is headquartered in San Diego, CA.

RBNC Therapeutics, Inc. develops and commercializes therapies for individuals with brain diseases.

Treeline Biosciences, Inc. develops transformative precision medicines for patients with cancer. The company is based in Stamford, CT. The company was founded by Joshua H. Bilenker. Joshua H. Bilenker has been the CEO since incorporation.

Pretzel Therapeutics, Inc. is an American biotechnology company that develops therapies by utilizing mitochondrial biology. Pretzel Therapeutics is based in an undisclosed location and has research facilities in another undisclosed location. The company aims to develop treatments that address the genetic causes of mitochondrial dysfunction. The company was founded by academic experts in mitochondrial biology and is supported by a world-class investor syndicate. Jay Parrish has been the CEO of the company since 2021.

Orbital Therapeutics, Inc. is a company based in Cambridge, MA that aims to enhance health by utilizing RNA-based medicines to treat human diseases in innovative ways. The company is building a platform that combines RNA technology delivery methods, data science, and automation to develop a portfolio of medicines focused on vaccines, immunomodulation, protein replacement, and regenerative medicine. The company was founded by Drew Weissman, John M. Maraganore, Kristina M. Burow, Ravindra Majeti, Giuseppe Ciaramella, Eugene W. Yeo, Howard Y. Chang, and Carol Suh, with Giuseppe Ciaramella serving as the CEO since incorporation.